Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma, Renal Cell 2Zollinger-Ellison Syndrome 1Uterine Cervical Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Melanoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Gastrointestinal Cancer Metastatic 1Epstein-Barr Virus Infections 1Carcinoma, Hepatocellular 1Blast Crisis 1Adenoma, Islet Cell 1

Interventions

Sunitinib 64Nivolumab 54Sorafenib 38Bevacizumab 35Axitinib 35pembrolizumab 34Everolimus 30cabozantinib 29pazopanib 26aldesleukin 26Ipilimumab 23Interleukin-2 19Specimen Handling 17Magnetic Resonance Spectroscopy 17Gemcitabine 17lenvatinib 16Interferon-alpha 15Interferon alpha-2 13Radiosurgery 12Cyclophosphamide 12fludarabine phosphate 11atezolizumab 10durvalumab 8Introns 8Erlotinib Hydrochloride 8Biopsy 8temsirolimus 7avelumab 7Radiotherapy 7Capecitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Renal Cell × Interferons × Clear all
NCT00678288 2014-12-11

A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.

Bayer

Phase 2 Terminated
16 enrolled 6 charts
Genitourinary

Carcinoma, Renal Cell

NCT00117637 2014-10-31

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

Bayer

Phase 2 Completed
189 enrolled 44 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡